Generic Name and Formulations:
Acetaminophen 320.5mg, caffeine 30mg, dihydrocodeine bitartrate 16mg; caps.
Indications for TREZIX:
Moderate-to-moderately severe pain.
Individualize. 2 caps every 4 hours as needed. Max 10 caps/24 hours.
Post-op pain management in children who have undergone tonsillectomy and/or adenoidectomy. Significant respiratory depression (in unmonitored settings or without resuscitative equipment). Acute or severe bronchial asthma or hypercapnia. Paralytic ileus.
Risk of respiratory depression and death related to ultra-rapid metabolizers of codeine (esp. children in post-op tonsillectomy and/or adenoidectomy). Risk of hepatotoxicity may result with acetaminophen doses >4g/day or involving more than one acetaminophen-containing product. Discontinue if anaphylaxis or hypersensitivity reactions occur. Hypotension. Volume depletion. Circulatory shock. Abuse potential. Adrenocortical insufficiency (eg, Addison’s disease). Asthma. Coma. COPD or decreased respiratory reserve (eg, emphysema, severe obesity, cor pulmonale, kyphoscoliosis). Seizures. Delirium tremens. Head injury. Increased intracranial pressure. Myxedema or hypothyroidism. Prostatic hypertrophy or urethral stricture. Toxic psychosis. Acute abdomen. Biliary tract disease. Pancreatitis. Drug abusers. Acute alcoholism. Use lowest effective dose for shortest duration. Renal or hepatic impairment. Elderly. Debilitated. Malnourished. Pregnancy (Cat.C). Labor & delivery, nursing mothers: not recommended.
Potentiation with alcohol, other opioids, sedatives, hypnotics, muscle relaxants, general anesthetics, centrally-acting antiemetics, tranquilizers; reduce dose of one or both drugs. Concomitant phenothiazines or drugs that compromise vasomotor tone; caution. Concomitant MAOIs may cause CNS excitation, hypertension. May be antagonized by agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, buprenorphine). Increased hepatotoxicity risk with anticonvulsants (eg, phenytoin, barbiturates, carbamazepine) or isoniazid. May potentiate warfarin. May be potentiated by disulfiram, quinolones (eg, ciprofloxacin). May antagonize phenobarbital, aspirin.
Analgesic + stimulant + opioid.
Lightheadedness, dizziness, drowsiness, headache, fatigue, sedation, sweating, nausea, vomiting, constipation, pruritus, skin reactions, respiratory depression, orthostatic hypotension, cough suppression, confusion, urinary retention, hepatotoxicity, anxiety, excitement, insomnia, irritability, palpitations, tachycardia, tinnitus.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|